Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle'

Executive Summary

The top leadership of Cipla, Dr Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries and Lupin discuss automation roadmaps, strategies for a play in new modalities and talent acquisition and retention amid the global "great resignation."

You may also be interested in...



India’s Top Deck Backs Patent Box Policies, Four-Prong Strategy

C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.

McKinsey Exec On Technology Trends Reshaping Future Factories

McKinsey senior partner Joseph Hughes outlines the shape of things to come as new technologies transform life sciences manufacturing, while new modalities around cell-, gene- and RNA-based therapeutics could have “profound implications” on global operations networks.

J&J’s Gorsky Puts Spotlight On Big Picture Potential Of Asia, New Technologies

Keep your eyes on Asia, both for groundbreaking innovation and huge market opportunities, says Alex Gorsky, executive chairman of Johnson & Johnson. He also outlines exciting possibilities as biology and chemistry are being “fundamentally digitized.”

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel